Conducting clinical trials in Eastern Europe can shorten drug development time, thus reducing the cost for pharmaceutical companies. Since marketing prospects in many Eastern European countries are promising, acquainting physicians and health authorities with a new drug as early as possible may well be worthwhile. The advantages and disadvantages of conducting clinical trials in Eastern Europe are covered.
SzczeklikA.Differences in Prevalence of Diseases between Eastern and Western Countries: Unmet Therapeutic Needs and Patients who may Benefit from New Drug Development. Presented at the DIA Workshop “Renaissance in Central and Eastern Europe: Unprecedented Pharmaceutical Industry Opportunities in the 1990s,” September 21-23, 1992, Warsaw.
4.
SmetiskoM.Pharmaceutical Industry and Drug Market in Croatia. Presented at the Forum Seminar “Die Pharma-Märkte Südosteuropas,” Forum—Institut für Management, September 17, 1993, Vienna.
5.
NatorffL.Why Conduct Clinical Trials in Central/Eastern Europe? Presented at the DIA Workshop “Conducting Clinical Trials in Central/Eastern Europe?” December 6–8, 1993.
6.
SykovaEVadaszIKrusinskaE. Presented at the DIA Workshop “Renaissance in Central and Eastern Europe: Unprecedented Pharmaceutical Industry Opportunities in the 1990s,” September 21-23, 1992, Warsaw.
7.
Good Clinical Practice for Trials on Medicinal Products in the European Community.CPMP Working Party on Efficacy of Medicinal Products, Commission of the European Communities; Brussels1991: Document 111/3976/88-EN (Final).
8.
Chemische Rundschau 40, Nr. 30/31, 1985, quoted from Gassen HG, König B. Perspektiven einer biologisch orientierten Industrie in Deutschland. In: Kontakte (Darmstadt) 1994 (1), ISSN 0172-8717:3.
